The progression from hypertension to heart failure

American Journal of Hypertension

Volumn 10, Issue 10 II SUPPL., 1997, Pages

  Deedwania, Prakash C ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Angiotensin converting enzyme inhibitors; Heart failure; Hypertension; Left ventricular failure; Left ventricular hypertrophy

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOSINOPRIL;

ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COUGHING; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; PRIORITY JOURNAL;

EID: 0030856128     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0895-7061(97)00335-x     Document Type: Article

References (75)

1. Yamani M, Massie BM. Congestive heart failure insights from epidemiology, implications for treatment . Mayo Clin Proc. 63:1993;1214-1218.
2. Ho KKL, Pinsky JL, Kannel WB, et al. The epidemiology of heart failure the Framingham study . J Am Coll Cardiol. 22(suppl A):1993;6A-13A.
3. Kannel WB, Ho K, Thom K. Changing epidemiological features of cardiac failure. Br Heart J. 72(suppl):1994;S3-S9.
4. McKee PA, Castell WP, McNamara PM, Kannel WB. The natural history of congestive heart failure the Framingham Heart Study . N Engl J Med. 285:1971;1441-1446.
5. Eriksson H, Svardsudd K, Larsson B, et al. Risk factors for heart failure in the general population the study of men born in 1913 . Eur Heart J. 10:1989;647-656.
6. Gillum RF. Epidemiology of heart failure in the United States. Am Heart J. 126:1993;1042-1047.
7. Kannel WB, Belanger AJ. Epidemiology of heart failure. Am Heart J. 121:1991;951-957.
8. Levy D, Larson MG, Vasan RS, et al. The progression from hypertension to congestive heart failure. JAMA. 275:1996;1557-1562.
9. Tarazi RC. The heart in hypertension. New Engl J Med. 312:1985;308.
10. Frohlich ED: The heart in hypertension, in Genest I, Kuchel O, Hamet P, Cantin M (eds): Hypertension: Pathophysiology and Treatment, ed 2. McGraw-Hill Book Co, New York, 1983, pp 791-810.
11. Tazari RC, Frohlich ED. Is reversal of cardiac hypertrophy a desirable goal of antihypertensive therapy? Circulation. 75(suppl I):1987;I-114-I-117.
12. Messerli FH: The Heart in Hypertension. Yorke Medical Books, New York, 1987, p 27.
13. Hartford M, Wikstrand JC, Wallentin I, et al. Left ventricular wall stress and systolic function in untreated primary hypertension. Hypertension. 7:1985;97-104.
14. De Simone G, Di Lorenzo L, Constantino G, et al. Supernormal contractility in primary hypertension without left ventricular hypertrophy. Hypertension. 11:1988;457-463.
15. Hammond IW, Devereux RB, Alderman MH, et al. The presence and correlates of echocardiographic left ventricular hypertrophy among employed patients with uncomplicated hypertension. J Am Coll Cardiol. 7:1986;639-650.
16. Kannel WB, Wolf PA, Garrison RJ (eds): Some risk factors related to the annual incidence of cardiovascular disease and death in polled repeated biennial measurements: Framingham heart study, 30 year follow-up. Bethesda, MD, National Institutes of Health 1987, section 34. Publication NIH 87-2703.
17. Kannel WB. Prevalence and natural history of electrocardiographic left ventricular hypertrophy. Am J Med. 75(suppl 3A):1983;4-11.
18. Kannel WB, Gordon T, Offutt D. Left ventricular hypertrophy by electrocardiogram prevalence, incidence and mortality in the Framingham study . Ann Intern Med. 11:1989;89-101.
19. Levy D, Garrison RJ, Savage DD, et al. Left ventricular mass as incidence of coronary heart disease in an elderly cohort the Framingham study . Ann Intern Med. 110:1989;101-107.
20. Kannel WB, Dannenberg AL, Levy D. Population implications of electrocardiographic left ventricular hypertrophy. Am J Cardiol. 60(suppl 1):1987;851-931.
21. Rodeheffer RJ, Jacobsen SJ, Gersh BJ, et al. The incidence and prevalence of congestive heart failure in Rochester, Minnesota. Mayo Clin Proc. 68:1993;1143-1150.
22. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks US population data . Arch Intern Med. 153:1993;598-615.
23. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease, part 1 prolonged differences in blood pressure corrected for the regression dilution bias . Lancet. 355:1990;765-774.
24. Fresco C, Avanzini F, Bosi S, et al. Prognostic value of a history of hypertension in 11,483 patients with acute myocardial infarction treated with thrombolysis. J Hypertens. 14:1996;743-750.
25. Tarazi RC, Faoud FM. Assessment of cardiac status in hypertensive patients. J Hypertens. 3(suppl 2):1985;S27-S31.
26. Iriarte MM, Olea JP, Sagastagoitia D, et al. Congestive heart failure due to hypertensive ventricular diastolic dysfunction. Am J Cardiol. 76:1995;43D-47D.
27. Messerli FH, Ventura HO, Elizardi DJ, et al. Hypertension and sudden death increased left ventricular ectopic activity in left ventricular hypertrophy . Am J Med. 77:1984;18-22.
28. McLenachan JE, Henderson E, Morris KI, Dargie HJ. Ventricular arrhythmias in patients with hypertensive left ventricular hypertrophy. N Engl J Med. 317:1987;787-792.
29. Messerli FH. Antihypertensive therapy - going to the heart of the matter. Circulation. 81:1990;1128-1135.
30. Smith VE, Katz AM. Ionotropic and lusitropic abnormalities in the genesis of heart failure. Eur Heart J. 4(suppl A):1983;7-17.
31. Dougherty AH, Naccarelli GV, Gray EL, et al. Congestive heart failure with normal systolic function. Am J Cardiol. 54:1984;778-782.
32. Lorell BH. Significance of diastolic dysfunction of the heart. Ann Rev Med. 42:1991;411-436.
33. Weijnberg MP, Feskens EJM, Kromhout D. Blood pressure and isolated systolic hypertension and the risk of coronary heart disease and mortality in elderly men (the Zutphen Elderly Study). J Hypertens. 14:1996;1159-1166.
34. Vogt M, Strauer BE. Systolic ventricular dysfunction and heart failure due to coronary microangiopathy in hypertensive heart disease. Am J Cardiol. 76:1995;48D-53D.
35. Westerhof N, O'Rourke MF. Hemodynamic basis for the development of left ventricular failure in systolic hypertension and for its logical therapy. J Hypertens. 13:1995;943-952.
36. Chen CH, Ting CT, Lin SJ, et al. Different effects of fosinopril and atenolol on wave reflections in hypertensive patients. Hypertension. 25:1995;1034-1041.
37. Dubus I, Samuel J-L, Swynghedauw B. Origins and mechanisms of heart failure in hypertensive patients left ventricular remodelling in hypertensive heart disease . Eur J Heart. 14(suppl J):1993;76-81.
38. Brilla CG. The cardiac structure-function relationship and the renin-angiotensin-aldosterone system in hypertension and heart failure. Curr Opin Cardiol. 9(suppl 1):1994;S2-S11.
39. Seravalle G, Cattaneo BM, Giannattasio C, et al. RAA system and cardiovascular control in normal subjects, hypertensives and patients with congestive heart failure. J Hum Hypertens. (suppl 2):1993;S13-S18.
40. Collins R, Peto R, McMahon S, et al. Blood pressure, stroke and coronary heart disease II short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context . Lancet. 335:1990;827-838.
41. Hebert P, Moser M, Mayer J, Hennekens C. Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease. Arch Intern Med. 153:1993;578-581.
42. Moser M, Hebert PR. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol. 27:1996;1214-1218.
43. Moser M, Gifford F. Why less severe degrees of hypertension should be treated. J Hypertension. 3:1985;437-447.
44. Sytkowski PA, D'Agostino RB, Belanger AJ, et al. Secular trends in long-term sustained hypertension, long-term treatment, and cardiovascular mortality The Framingham heart study 1950 to 1990 . Circulation. 93:1996;697-703.
45. Chobanian AV. Have long-term benefits of antihypertensive therapy been underestimated? Circulation. 93:1996;638-640.
46. Kleber FX, Wensel R. Current guidelines for the treatment of congestive heart failure. Drugs. 51:1996;89-98.
47. Majid PS, Sharma B, Taylor SH. Phentolamine for vasodilator treatment of severe heart failure. Lancet. ii:1971;719-723.
48. Giles TD. Lisinopril in the treatment of congestive heart failure. J Hum Hypertens. 3:1989;83-87.
49. A placebo-controlled trial of captopril in refractory chronic congestive heart failure. J Am Coll Cardiol. 2:1983;755-763.
50. Creagger MA, Massie BM, Faxton DP, et al. Acute and long term effects enalapril on the cardiovascular response to exercise and exercise tolerance in patients with congestive heart failure. J Am Coll Cardiol. 6:1985;163-170.
51. Effect of enalapril on mortality in severe congestive heart failure Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS) . N Engl J Med. 316:1987;1429-1435.
52. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 325:1991;293-302.
53. Pfeffer MA, Braunwald E, Moyé LZ, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction Results of the Survival and Ventricular Enlargement Trial . N Engl J Med. 327:1992;669-677.
54. Deedwania PC. Prevention of heart failure and postinfarction remodelling. Cardiol Clin. 12(1):1994;155-164.
55. Deedwania PC, Amsterdam EA, Vagelos RH, et al. Evidence-based, cost-effective risk stratification and management after myocardial infarction. Arch Intern Med. 157:1997;273-280.
56. Perani G, Muggia, Martigoni A, et al. Increase in HDL-cholesterol in hypertensive patients treated with enalapril. Clin Ther. 9:1987;635-639.
57. Paul SD, Kuntz KM, Eagle KA, et al. Costs and effectiveness of angiotensin converting enzyme inhibition in patients with congestive heart failure. Arch Intern Med. 154:1994;1143-1149.
58. Kjekshus J, Swedberg K. Tolerability of enalapril in congestive heart failure. Am J Cardiol. 62:1988;67A-72A.
59. O'Connel JB, Bristow MR. Economic impact of heart failure in the United States time for a different approach . J Heart Lung Transplant. 13:1994;S107-S112.
60. Raijfer SI. Perspective of the pharmaceutical industry on the development of new drugs for heart failure. J Am Coll Cardiol. 22(suppl A):1993;198A-200A.
61. Dunn FG, Oigman W, Ventura HO, et al. Enalapril improves systemic and renal haemodynamics and allows regression of left ventricular mass in essential hypertension. Am J Cardiol. 53:1984;105-108.
62. Garavaglia GE, Messeli FH, Nunez BD, et al. Immediate and short-term cardiovascular effects of a new converting enzyme inhibitor (lisinopril) in essential hypertension. Am J Cardiol. 62:1988;912-916.
63. Ventura HO, Frohlich ED, Messerli FH, et al. Cardiovascular effects and regional blood flow distribution associated with an angiotensin converting enzyme inhibitor (captopril). Am J Cardiol. 55:1985;1023-1026.
64. Kirpizidis HG, Papazachariou GS. Comparative effects of fosinopril and nifedipine on regression of left ventricular hypertrophy in hypertensive patients a double-blind study . Cardiovasc Drugs Ther. 9:1995;141-143.
65. Effect of captopril on left ventricular mass and function in hypertensive patients and in the rat. Postgrad Med J. 62(suppl I):1986;85-89.
66. Nakashima T, Faoud FM, Tarazi RC. Regression of left ventricular hypertrophy from systemic hypertension by enalapril. Am J Cardiol. 53:1984;1044-1049.
67. Dzau VJ. Angiotensin converting enzyme inhibitors and the cardiovascular system. J Hypertension. 10(suppl):1992;S3-S10.
68. Zusman RM. Angiotensin-converting enzyme inhibitors: more different than alike? Focus on cardiac performance . Am J Cardiol. 72:1993;25H-36H.
69. David D, Jallad N, Germino FW, et al. A comparison of the cough profile of fosinopril and enalapril in hypertensive patients with a history of ACE inhibitor associated cough. Am J Therap. 2:1995;806-813.
70. Duchin KL, Kripalani KJ, Marino MR, et al. Review of the pharmacokinetics of fosinopril in special populations. Drug Invest. 3(suppl 4):1991;18-24.
71. Zuchelli P, Sclarovsky S, Paz R, et al: Comparison of the pharmacokinetics of fosinoprilat and lisinopril in patients with congestive heart failure and chronic renal insufficiency. (Submitted for publication).
72. Vetter W. Treatment of Genile hypertension Fosinopril in Old Patients Study (FOPS) . Am J Hypertens. 10(10, suppl):1997;255S-261S.
73. Leonetti G, Trimarco B, Collatina S, Tosetti A. An effective approach for treating elderly patients with isolated systolic hypertension results of an Italian multicenter study with fosinopril . Am J Hypertens. 10(10, suppl):1997;230S-235S.
74. Blumenthal M. Treatment of congestive heart failure experience with fosinopril . Am J Hypertens. 10(10, suppl):1997;289S-298S.
75. Mancia G, Grannattasio C, Grassi G. Treatment of heart failure with fosinopril an angiotensin converting enzyme inhibitor with a dual and compensatory route of excretion . Am J Hypertens. 10(10, suppl):1997;236S-241S.